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ABSTRACT

G-protein coupled receptors (GPCRs) are currently the largest class of
membrane receptors and are targeted by a majority of the modern drug
therapeutics. In addition, they partake in many physiological and pathological
processes such as inflammation, growth, and hormone responses. Most
importantly, GPCRs are targets of many disease-specific pathways such as
Alzheimers, hypertension, leukemia, and depression. As a result, there is an
immense interest in studying GPCRs as this area provides further knowledge into
the specific disease pathways and allows the discovery of novel therapeutics. In
order to have a better understanding of pathways, scientists have studied GPCR
activation. The prostanoid receptors are of great interest because they
coordinate a vast range of physiological processes such as regulating
cardiovascular pathways, modulating neuronal activity and controlling immune
responses. We collaborated with Multispan Inc., a biotech company focusing
exclusively on drug discovery research targeting GPCRs, to monitor the agonistinduced internalization of GPCRs from the prostanoid family through live cell flow
cytometry. From our experimental results, we have observed over 50 percent
internalization for the EP1 and EP4 receptors within 60 minutes after being
activated by iloprost and PGE2 respectively. Our initial experimental results have
also shown over 40 percent internalization for the TP receptor within 120 minutes
after exposure to PGD2. Overall, we have been able to utilize Multispan’s
proprietary cell lines to overexpress a few of the prostanoid receptors. These
assays are powerful tools for the discovery of novel therapeutics, as they enable
the testing against libraries and screening from a few thousand to a few million
compounds.

Keywords: GPCR, prostanoid, agonist, internalization, flow cytometry, iloprost,
PGE2
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1.0 INTRODUCTION
1.1 Background/Motivation
G-protein coupled receptors (GPCRs) are the largest and most diverse class of
membrane receptors. One of the main functions of GPCRs is to trigger
secondary messengers such as cyclic adenosine monophosphate (cAMP) or
calcium ion channels. The activation of the secondary messengers helps
regulate body functions such as sensation, growth and hormone responses.1 In
order to trigger secondary messengers, the GPCR must be activated by the
binding to a ligand. As a result, there is an immense interest in studying the
specific pathways of GPCRs. GPCRs also have an extremely large market of
about $122 billion by 2018. Currently, over 250 GPCRs have been identified and
150 GPCRs to de-orphanize, which presents a tremendous opportunity for future
research.2 The biggest motivation for GPCR research is that they are responsible
for many disease-specific pathways such as endocrine and vision disorders.3 As
a result, the industry has a demand for better therapeutic discovery tools, such
as assays, as a new platform for monitoring receptor activation. These new
platforms would lead to a better understanding of the disease pathways. By
developing a better understanding of disease pathways, researchers will be able
discover novel therapeutics for the treatment of these diseases. Please refer to
the glossary of terms in

1.2 Project Goals & Objectives
Our aim is to develop quantitative measurements of receptor response for novel
therapeutics. This is done first through the development of assays to measure
the internalization of GPCRs. The process of internalization begins when the
GPCR is activated through the binding of a specific ligand at the site by the Nterminus. By measuring the EC50 values for internalization for each specific
GPCR, we can better understand an entirely new platform of receptor activation.
In addition to EC50 values, we must obtain the specific time intervals at which
internalization occurs. By obtaining these key pieces of information, we hope to
establish new internalization assays using Multispan Inc.’s existing platforms. As
1

interns at Multispan Inc., we are responsible for developing assays for the
GPCRs within the prostanoid family. Our aim is to obtain valid EC50 values for
the activation of these two families of GPCRs. EC50 values must be reproducible
within three folds of each other. If the previous goals are achieved, our future
goals would be to perform antagonist testing to inhibit the internalization of the
GPCRs. If the previous two tasks are accomplished we can then use this
platform to test against pharmacological libraries for novel therapeutics.

1.3 Review of Field/Literature
The following paragraphs contain our literature findings on the general structure
of GPCRs and the specific functions and diseases associated with prostanoid
receptors. In addition, we researched on the ligands that have been used for
specific GPCRs for other assays such as calcium and cAMP assays. These
findings helped us in our agonist selection along with targeting the time frame for
running these experiments. Most importantly, our literature research helped us
select the GPCRs with the highest chance to internalize with the available
agonists that we have.

1.3.1 General Structures of GPCRs
GPCRS are composed of seven hydrophobic transmembrane domains which
include an extracellular
amino terminus and an
intracellular carboxyl
terminus. A ligand
binding domain, located
close to the extracellular
amino terminus, causes
the activation the GPCR
when a ligand binds to
the region.4
Figure 1: Schematic showing the different steps in
clathrin-coated endocytosis
2

The process of internalization occurs when a ligand binds to the GPCR. Clathrindependent GPCR internalization occurs when an agonist binds to the receptor
and triggers conformational change because it transforms the receptors into
substrates of the GRKs. The GPCRs that are occupied by the ligand become
phosphorylated and at the cytosolic Serine and Threonine residues. The
phosphorylated ligand-complex then rapidly recruits β-arrestins which disrupts
further signaling to the G proteins. β-arrestins then promote clathrin-dependent
endocytosis by binding to the GPCR with adaptor proteins to form the earlycoated pit. As illustrated by Figure 1, more clathrin and adaptor proteins continue
to accumulate and the clathrin-coated pit detaches from the plasma membrane
with the addition of dynamin. The ligand-receptor clathrin complex then
internalizes and travels along the internalization pathway. The clathrin and
adaptor proteins then uncoat from the complex and from this point, at least two
possibilities exist; the receptors are either removed from ligands and recycled
back to the cell surface or the receptors are transferred to late endosomes which
readied them for lysosomal degradation.5

1.3.2 Prostanoid Receptors
Prostanoid receptors are part of a family of active lipids which can be further
divided into three main groups: prostaglandins, prostacyclins, and thromboxanes.
They are sometimes referred to as local hormones which act in an autocrine
manner to control the effects of other hormones in the circulation. They
coordinate a vast range of physiological processes which ranging from producing
cardiovascular effect to modulating neuronal activity, and controlling inflammation
and immune responses. The receptors express their activity by interacting with
G-protein-linked receptors divided into five classes. PGE2(EP1 through EP4),
PGD2 (DP1 and DP2), PGF2α (FP), PGI2 (IP) and TXA2 (TP). The initial effect in
activating these receptors is the increase or decrease in the uptake rate of cAMP
or calcium ions. The activation of the receptor further translates into regulating
the physiological and pathological processes of the body.6 The disease pathways
associated with prostanoids include: atherothrombosis, aortic aneurysm, cancer,
3

hypertension, and leukemia. An example of how prostanoid receptors may play a
direct role in cancer is displayed in mice model. Mice models lacking EP 1, EP2, or
EP4 have a lower chance of disease in carcinogenesis models.7
1.3.3 Selection of agonists for prostanoid receptors
Our approach towards agonist selection would be to research on other assays
that have been done for the specific receptor. Prostaglandin E 2 (PGE2) has been
found to be an effective agonist to trigger internalization for the EP4 receptor. In
fact, it has been observed that there is about 20 percent internalization for HEK
293-EBNA-HA-hEP4 transfected with dominant negative β-arrestin 1. In addition,
1µM of PGE2 was used over the course of 60 minutes.8 Although the specific cell
line is different along with the transfected components, these are great starting
points to construct our internalization assay for EP4 receptor. EP1 and IP
receptors have been found to have an extremely high binding affinity for iloprost.
High binding affinity may potentially play a large role in internalization as the
experiments within an article by Whittle et al., has tested the EC50 values for
cAMP and calcium assays. On the other hand, iloprost has a low affinity for FP,
EP3, and EP4 receptors.9 PGD2 has been found to be an effective agonist for DP1
and DP2.10 In addition, the potency of the agonists found above has been
validated through the IUPHAR database.

4

2.0. SUBSYSTEM CHAPTERS

2.1. Technology Overview

Figure 2. A linear flow diagram illustrating the technology and processes
involved in the entire experiment. First, the receptor of interest is chosen
and then the ligand potent to the receptor is incubated with the cells
overexpressing the desired receptor for a given amount of time. Next,
subsequent washes are performed and the cells are stained with anti-FLAG
tag antibodies. After antibody staining, the cells are ready for analysis under
the flow cytometer.
Our experiment is composed of several components: receptor and ligand
selection, incubation, subsequent washes, antibody staining, and analysis of
under the flow cytometer. Serial dilutions are performed to prepare the drug
compounds and a detailed description can be found in chapter 3.1. The drug
compounds are then incubated in 37 degrees Celsius with the cells
overexpressing the receptor of interest and then subsequent washes are
performed. The cells are then stained with the anti-FLAG tag antibody and
incubated for 30 to 60 minutes. More subsequent washes are performed and the
cells are resuspended in FACS buffer and ready for analysis under the flow
cytometer. The data obtained is then analyzed in Graph Prism 4 to create the
EC50 plots.
2.3 Customer Needs and Requirements
2.3.1. Company Needs
When we first started the assay development, we realized that Multispan Inc.,
was the customer who we need to prioritize first because we knew very little
about the technology and the product market. As a result, we interviewed three
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different individuals within the company and created three different
questionnaires which can be found in Appendix A. Instead of sending out emails, we interviewed each one individually so that we immediately clarify our
questions if they are unclear. They individuals from the company range from
different areas of specialties such as research and development, management
and sales.
We first interviewed our industry advisor and Multispan Inc’s CEO, Dr. Helena
Mancebo. Her feedback would lead us to our main task and what is expected
from our team. In addition, we would find out what we need to do to address the
needs of Multispan Inc’s customers. Dr. Helena Mancebo provided us with the
following information:

Currently, there is not a direct competitor offering the same internalization assays
as Multispan Inc. The results of each internalization assay must be reproducible
with less than 3 fold differences for EC50s for IC50s in 3 independent
experiments for it to be considered “validated.” There is a need to develop
validated internalization assays for all targets within each assigned receptor
family.

The second individual who is interviewed was Dr. Ricai Han, who was the Senior
Scientist at Multispan Inc. Although Dr. Han has not directly worked with
Prostanoid receptors, he was able to provide us with some of his insights from a
researcher’s perspective. According to Dr. Han, Multispan Inc, is unaware of the
affinity of the receptor or any other specific information regarding the drugs sent
by companies such as Johnson and Johnson for testing. They also do not know
which compound could trigger signal transduction from the GPCR. In order to
perform internalization assays on these drugs the researcher must characterize
the function and the activities of how it could affect surface expression in addition
to finding the internalization factor. Without performing the previous steps, it

6

would be extremely difficult to select for the most suitable GPCR that the drug
acts upon.

Finally, we interviewed Dr. Radhika Venkhat, who is the R & D Manager at
Multispan Inc. Dr. Venkhat has provided us with an entirely different perspective
as she is the expert in internalization assay at the company. According to
Radhika, she has worked with internalization many different types of receptor
and the approach has to be paired with understanding the different properties of
each specific receptor. She has only worked with DP2 from the family that we are
assigned to work on. She explains to us that one of the first issues we will face is
the selection of the specific agonist or antagonists to use for each assay. These
are chosen based on those reported from literature research and analysis. Some
may require internalization with other receptors or it is derived from external
factors. The second issue is the framing the time point of internalization for an
unknown compound with a receptor. The main reason is that for some receptors,
there is a rapid recycling time frame for some receptors and it is essential to
grasp the window of internalization in order for us to not miss it. She advised our
group to keep practicing on the technique and running the assays as once the
technique is mastered and we learn more about the theoretical component from
the literature, we will have a much better understanding on how to set up the
assays.

2.3.2. Product Design Specification
Our Product Design Specification is broken into 3 categories: the assay itself,
confidentiality, and deliverables. A detailed table is provided in Appendix A. The
assay itself further contains 3 subclasses: EC50 or IC50 (optional) accuracy,
complete validation of all family receptors, and reproducibility. Confidentiality is
further divided into 3 subclasses: proprietary procedures, materials and
information, and IP protection of ligand specifics from pharmaceutical companies.
The last category is deliverables which includes one subcategory of having
complete data under final conditions.
7

2.4 Benchmarking Results
Currently, there are not any known existing products that are similar to the
internalization assays offered by Multispan. The most significant advantage of
live cell flow cytometry is that it allows the accuracy of the quantitative analysis to
go down to counting each individual cell over a specific time period. Currently,
there isn’t another testing method that is able to provide such accuracy. Although
this testing method is lengthier compared to the alternatives, the optimum
accuracy obtained from the measurements makes this a worthwhile tradeoff.
Other GPCR companies perform assays on different GPCR lines which are not
screened by Multispan Inc. The testing methods used are also different as none
of them currently incorporate the same platform with live cell flow cytometry and
fluorescence tagging as Multispan Inc. Another indirect competitor would be
virtual drug screening which is extremely promising in that it reduces the costs
and time for novel therapeutic screening but it requires the assays to be done
and validated previously. Table 1 below compares the advantages and
disadvantages of the testing method that Multispan Inc. uses to the other
available testing methods.

Table 1. Analysis of different testing methods: Table comparing both the
advantages and the disadvantages between the other available testing methods
and Multispan Inc.’s testing platform
Testing Method

Advantages

Disadvantages

Multispan’s platform

Flow cytometry enables

Assay is more time

Live cell flow cytometry

precision down to each

consuming for some

individual cell for monitoring

receptors

internalization and provides
specific time points for
internalization
Other platforms

Often little complex analysis
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Quantitative results

(Infrared fluorescence)

involved and direct functional

are not as precise

read out.

down to individual cell
count.

Virtual Drug Screening

Can cut costs and time and is

This requires a valid

and provide a theoretical result existing database to
build on and is not
effective yet as a
predictor tool.

2.5 Key System Level Issues
2.5.1. Main Issues:
The main issue of the internalization assay system revolves around the
uncertainty of how the ligand will internalize. Although the selection of the ligand
is made based upon known publications, the way of which these receptors
internalized is still unknown. The success of using a particular ligand for different
assay does not imply that the similar success will carry over for internalization. In
addition, it is more economical to use the ligands that Multispan Inc. already has
rather than buying more since it’s not guaranteed that those will work really well.
To further complicate matters, some G protein-coupled receptors require
homodimerization or heterodimerization with another receptor in order to
internalize into the cellular membrane. After figuring out the specific mechanism
and conditions which triggers a ligand to internalize, the next issue would be to
pinpoint the time frame at which this event occurs. Some receptors may
internalize within 5 minutes while others may require a much lengthier period
such as 3 hours in order for the process to occur. Although an EC50 curve is able
to guide us into the right time point, knowing the exact window would cut down
costs and time for the experiments.

2.5.2. System Options:
Agonist selection: The selection of the agonist is done through researching
similar experiments which have been performed on the specific prostanoid
9

receptor. We will work on the receptors with known agonists for similar
experiments first before we move onto the other ones.

Concentration: The concentration of the agonist compound can be varied
accordingly. A higher starting compound concentration would be used if the
agonist has a low affinity towards the receptor. If the agonist has a high affinity
towards the receptor, a low starting concentration would be required.

Specific Time period: The time period of internalization is obtained through
literature research which contains time intervals for other assays such as
calcium, and cAMP. For receptors that contain little information a time window of
2 hours is general accepted.

2.5.3. Tradeoffs:
Currently, the experiment contains several paramaters which need to be taken in
consideration as the assays may completely head towards a different direction
with the inclusion or inclusion of these factors. Table 2 highlights the pros and the
cons of three options such as cell fixation, flow cytometery, and an economical
agonist selection.

Table 2. Tradeoffs: Comparison between each process option and the decision
made in the end with both the pros and cons in consideration
Option

Pros

Cons

Decision

Fixing the cells

Allows assays

Too many cells are

Fixing will not

with

to be done at

lost in the process and

be considered

paraformaldehyde

later time

you need to monitor

for experiment

the timeframe carefully
Live Cell Flow

Providing

Much more time

Flow cytometry

Cytometry

analysis down

consuming than using

will be used

to each

a plate reader

because of

individual cell

accuracy
10

Using alternative

More

Assays may not work

Alternative

agonists over the

economical to

well with alternatives

agonists will be

most potent ones

use what the

because they are not

used first before

found in literature

company has

as potent with the

we venture into

first

receptor

buying the most
potent ones
found in
literature

2.6 Team and Project Management
2.6.1. Project Challenges and Constraints
In any group project, challenges and constraints are inevitable but they must be
taken in consideration and solved before the project can progress. The major
constraint for most projects is the management of the given budget. Fortunately,
most of the expensive compounds, cell lines, and reagents were provided by
Multispan Inc. By communicating with our industry advisor Helena Mancebo, on
a regular basis, we were able to avoid this issue for our project. The main
challenge that we faced is time constraint. As seniors, we are faced with the
challenge of managing our time efficiently between working on our senior design
project, finding and securing jobs, completing graduate school applications, and
working on homework and group projects for classes. As a result, it was
extremely difficult on occasions for us to do our best work to meet the deadlines
for specific portions of our senior design project. To address this issue, we
scheduled regular group meetings and divided up the portions of the project to
get the assignments completed and turned in on time. It was difficult to meet up
as a group during the winter quarter because our class schedules were different
and we were extremely occupied with interviews and outside group projects. As a
result, we did not work together a lot for the project during the winter quarter
because the experiments required a large time slot and we did not have a
timeslot where we were both free. To remedy this issue, we updated each other
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regularly on the results and alternated with each other in changing the media and
trypsinizing our cell lines.

The second challenge that we faced is travel to and from the company. It
became extremely difficult for us to adjust to the long drive to and from Multispan
Inc., which is headquartered in Hayward, California. We must schedule our
classes wisely so that we have an ample amount of time to work on our assays
and to avoid the traffic hours when we are driving down to the company site. As a
result, we struggled immensely during the first quarter because of the limited
amount of time that we had to drive up to the company. Molecular biology
requires a lot of practice on the technique and we didn’t spend enough time the
first quarter. As a result, our main challenge for the most part is the limited
amount of time to research, develop adept lab skills, and to carry out
experiments. Although we had some cell culture experience prior to our project at
Multispan Inc., we never maintained multiple cell lines over months. The added
challenge is to maintain multiple cell lines 40 minutes away from where we live.
Contamination or unhealthy cells would cost both time and money to replace.

2.6.2. Team Budget
Because we are collaborating with Multispan Inc., on this project, it is fully funded
by the company because they provide costly cell lines, reagents and chemicals
for our project. For example, we shouldn’t take more than we actually need of
chemicals and reagents such as buffer, antibody, and drug compounds because
those are extremely expensive to waste. This would also push back the project if
we run out of chemicals and reagents. We also need to take an economical
approach when we run the experiments and use what we have first. It is not
logical to purchase the most potent agonist for a GPCR without using the
alternative agonists in the inventory because it’s guaranteed that the assay will
work extremely well with the agonist purchased. A detailed breakdown of the
budget can be found in Appendix
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2.6.3 Timeline
It is extremely important to construct and follow a project timeline to ensure that
the team is staying on top of things. However, it is often rare that the project
timeline is followed through in every step so the timeline has to be adjusted
accordingly. The main issue we faced for the timeline is on figuring out exactly
how much time is required for each specific task. As a result, we decided to
create an outline by a week-to-week basis which works a bit better for our
project. For the most part we were on task with the outline for the week-to-week
tasks but we fell short sometimes because we underestimated the amount of
time required to complete the task. A detailed outline can be found in Appendix
B.
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3.0. SYSTEMS INTEGRATION & VERIFICATION
3.1. Experimental Protocol
3.1.1. Expression of Prostanoid Receptors
Mammalian cells overexpressing the receptor of interest were acquired from
Multispan’s proprietary cell lines. Human embryonic kidney cells from the HEK
293T cell line have been modified to overexpress the receptor of interest. Figure
2 illustrates a general
structure of this specialized
cell line. The process of
receptor overexpression is
achieved by inserting a
plasmid containing the
complementary DNA
(cDNA) sequence coding
Figure 3. Plasmid used to overexpress
receptor of interest. This process was
performed at Multispan Inc.

for the receptor with the
addition of 24 base pair
coding for the octapeptide

FLAG-tag at the N-terminus. Plasmid also included selection markers puromycin
and ampicillin resistance to ensure the exclusive survival of cells that have taken
up the plasmid. The translation of this plasmid was ensured by the presence of a
strong promoter.
3.1.2. Activation of Prostanoid Receptors
There are three types of receptors in the prostanoid family, inhibitors of
adenalyse cyclase, contractile and relaxant receptors, with total of eight different
receptors identified. We have focused on the activation and the subsequent
internalization of Prostaglandin E Receptor 4 (EP4), Prostaglandin E Receptor 1
(EP1) and Thromboxane Receptor (TP). Utilizing available literature we have
identified compounds that activate each of these receptors, known agonists, as
well as reported EC50 values. We created dilutions of the compounds to
encompass a wide enough concentration window to achieve acceptable EC50
14

values; in this case a 1 in 5 dilution was appropriate. The EP4, EP1 and TP
receptors were activated with Prostaglandin E2 (PGE2), Iloprost, and
Prostaglandin D2 (PGD2), respectively. Table 1 below displays the different
starting concentrations and dilution rates were used for each compound to create
5x concentrations.

Table 3. Dilutions of the different compounds used for EP1, EP4, and TP. The
concentrations are in micromolarity with the highest concentration being five
times as concentrated so that the last dilution step causes the final concentration
to be 1x.
Receptor Agonist Dilution Highest 5x
Rate

Lowest

Concentration [5x] (µM)

Highest

Lowest

[1x] (µM)

[1x] (µM)

(µM)
EP1

Iloprost

1:5

5

3.2 e-4

1

6.5 e-5

EP4

PGE2

1:5

2.5

1.6 e-4

0.5

3.2 e-5

TP

PGD2

1:5

1000

6.4e-2

200

1.26e-2

In order to create the appropriate concentrations two steps dilution were made.
Research compounds are often dissolved in esters. To ensure the solubility of
the compounds, two steps dilutions were made first into dimethyl sulfoxide
(DMSO) followed by phosphate buffer saline (PBS). Precautions were taken to
ensure the final concentration of DMSO in the media during incubation periods
did not surpass 1% DMSO. The only exception to that is for iloprost because the
stock compound came in methyl acetate, an alcohol, so 3.5% DMSO is needed.
To control for the addition of DMSO to the cells the eighth and final well did not
contain agonist compound and was comprised of DMSO and PBS. This can be
compared to the seventh well to ensure the values are close.

During the incubation period cells overexpressing the receptors were incubated
with 40ul of Dulbecco's Modification of Eagle’s Media (DMEM) with 10% Fetal
Bovine Serum (FBS). Approximately 30,000 cells were placed in each well of a
15

96-well plate.10ul of the 5x dilutions, for a total of 50ul, were then added at 30
minute intervals ranging from 30 minutes to 120 minutes. The media was then
removed and washed with PBS three times, ensuring that everything is done on
ice, before proceeding with staining.

3.1.3. Tracking of Prostanoid Receptors
3.1.3.1. Antibody Staining
Due to the modification of the GPCR done my Multispan we can track its
expression on the surface using the Anti-FLAG-tag Antibody that bind to the
available Flag-tag. Anti-FLAG-tag Antibody (Prozyme α Flag 1.13mg/ml) was
acquired in 500x concentration. Anti-FLAG-tag Antibody was diluted in PBS to 1x
concentration and 150ul was added to each well. Cells were placed in a dark
refrigerator at 2 degrees Celsius for 30 minutes to allow antibodies to bind. Two
washes were then performed to remove Anti-FLAG-tag Antibodies with PBS and
one was with PBS + 1% Bovine Serum Albumin (BSA) to prepare samples for
FACS (Fluorescence-activated cell sorting) analysis.

3.1.3.2. Analysis of Internalization
Live cell flow cytometry was performed on the samples to analyze the bind of
Anti-FLAG-tag Antibodies
to the available Flag-tags
on the receptors present on
the surface of the cell.
Receptors that have been
activated and internalized
will correlate to a decrease
in the mean fluorescence
Figure 4. Loading of the cells overexpressing the
GPCR of interest on the BD scientific FACsort

intensity (MFI). Every cell
passes an interrogation

point in which the size, complexity and fluorescence are analyzed, we counted
2,000 of these events and obtained a MFI value for population comparison.
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Figure 4 illustrates the loading of a sample containing cells overexpressing a
GPCR receptor and pre-stained with antibody. The instrument used was a BD
Scientific FACSort and the analysis was run on BD CellQuest Pro software.
Parent cells in which the overexpressed receptor was induced were first
analyzed to provide background fluorescence

FLAG Tag Expressing Cells
Pre-Activation

Negative Control

Figure 5. Histogram showing the the MFI of the parental cells,
representing our negative control (black), and histogram FLAG tag
expressing cells prior to the addition of any drug compounds, taken as
positive control for the experiment (blue).

reading and calibration. The fluorescence in these cells is very low. We can then
analyze the fluorescence of cells with the overexpressed receptor-Flag-tag
a.

b.

complex. If the
cells are
correctly
expressing this
complex then
the Anti-Flagtag Antibody
will be able to

Figure 6. Side by side comparison showing how the Anti-FLAG
tag antibody works on (a) FLAG tag GPCRs and (b) parental
cells not expressing GPCRS
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bind and cause
an increase in
fluorescence.

Figure 5 above shows a histogram which includes the MFI for the parental cells
in black and the Flag tag expressing cells pre-activation. The MFI for the parental
cells is close to zero because the cells do not overexpress any GPCRs. As a
result, there is a need to subtract the addition of the parental cell MFI when
calculating the percentage of internalization. Figure 6a. above illustrates how the
Anti-flag tags bind to the Flag-tag GPCRs which increase the fluorescence
intensity. Figure 6b. illustrates how parental cells on attracts little or none of the
Anti-flag tags which is why the fluorescence intensity should be close to zero. A
few reasons why the MFI is not zero for the parental cells is due to the error in
the instrument and a few antibodies clinging to the parental cells.

3.2. Results
A BD scientific FACSort was used to analyze the mean fluorescence intensity
(MFI) of our experiments. The data is then plotted on Graph Prism version 4 and
fitted with a sigmoidal dose response varying slope. Log of the different
concentrations of the compound is plotted against MFI and In the first
experiment, we worked with EP4 receptor. We incubated the receptor with
prostaglandin E2 (PGE2) for 30 and 60 minutes. As observed in Figure 7b. over
50% internalization is observed during 30 minutes with an EC50 value of 5.21 x
10-9 M. Triplicate experiment was performed with the error bars representative
the deviation between each experiment’s concentrations. Figure 7b represents
the MFI converted to percentage of internalization by first subtracting each value
by the parental MFI and dividing by the MFI of each concentration by the
negative control. Figure 7a. and 7c. represents the MFI before the exclusion of
the parental MFI for each respective time interval. In Figure 7d. over 50%
internalization is also observed at 60 minutes with an EC50 value of 5.527 x 10-9
M. Because the EC50 values of both time points are extremely close to one
another, we cannot exclude either. The complete plot displaying the all the dose
response curves can be found in Appendix E.
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3.2.1. EP4 Internalization
b.

a.

c.

d.

Figure 7. EC50 plots of EP4 internalization at 30 and 60 minutes. (a) & (c)) Log of
the concentration of PGE2 in molarity is plotted against MFI before the exclusion of
parental MFI for both 30 and 60 minutes. (b) & (d) represents the log of
concentration of PGE2 plotted against percentage of internalization. Experiments are
done in triplicates.
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3.2.2. EP1 Internalization
a.

b.

Figure 8. EC50 plots of EP1 receptor internalization after 60 minutes. (a) Log
of concentration of iloprost in molarity plotted against MFI. (b) represents the
log of concentration of iloprost plotted against percentage of internalization.
Experiments are done in triplicates with error bars representing deviation
from each (a) MFI and (b) percentage of internalization.
In the second set of experiments, we incubated EP1 receptor with iloprost for 60
minutes. As observed in Figure 8b. over 50% internalization occurred with an
EC50 value of 4.27 x 10-10 M. Figure 8a. represents the EC50 value obtained for
MFI value without the exclusion of the parental cell MFI. The preliminary run
which includes 30 minutes can be found in Appendix E.

20

3.2.3. TP Internalization

120 minutes
120 minutes

Figure 9. EC50 plots of TP internalization after 120 minutes. (a) Log of
concentration of iloprost in molarity plotted against MFI. (b) represents the log of
concentration of iloprost plotted against percentage of internalization. Experiments
are done in duplicates with the error bars representing deviation from each (a) MFI
and (b) percentage of internalization

In our last successful experiment, TP receptor was incubated for 120 minutes
with prostaglandin D2 (PGD2). As observed in Figure 9b. over 40% internalization
occurred with an EC50 value of 5.95 x 10-6 M. Figure 9a. represents the EC50
value obtained for MFI value without the exclusion of the parental cell MFI. The
preliminary run which includes 30, 60, and 90 minutes can be found in Appendix
E.

3.2.4. Unsuccessful Experiments
Besides the EP1, EP4, and TP1 receptor, we also ran internalization assays for
EP2, DP1 receptor but little internalization was observed or the experiment was
not repeatable. The data for these experiments can be found in Appendix E.
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3.3. Analysis
3.3.1. EP4 Analysis
With over 50% internalization in 3 separate sets of experiments, the results
appear to be extremely promising in that the EC50 values fall within 3 fold of each
other. Our starting point for concentration was based on the International Union
of Basic and Clinical Pharmacology’s (IUPHAR) database which listed PGE2 as
having a binding affinity of 9.0 for EP4 for other assays. Internalization assays
tend to have a higher number and this binding affinity value is converted to the
negative power of base 10 to derive the exact concentration. As a result, an EC 50
of around 5.17 and 5.53 nM is reasonable. Because the deviation between the
MFI of each dilution is extremely small, we can conclude that internalization does
indeed happen within this time window and concentration. Neither 30 nor 60
minutes can be omitted because of the close proximity between the two EC 50
values.

3.3.2. EP1 Analysis
Over 50% internalization is observed in 3 separate sets of experiments and the
EC50 values of each individual experiment fall within 3 fold of each other. In
addition, our starting point for this assay was based on both IUPHAR and
Multispan Inc.’s value for other assays such as calcium and cAMP. Our EC50 of
4.27 x 10-10 M value even falls within 3 folds of Multispan Inc.’s EC50 value. None
of the error bars deviate too much so the assay is validated for this receptor with
iloprost as the agonist.

3.3.3. TP Analysis
We cannot entirely state that this assay has been validated because we were
only able to reproduce the results in 2 sets of experiments. The deviation in error
is extremely small which makes this assay promising. The different results
obtained from the third experiment may be due to pipetting error or slight
contamination in between. Repeating this experiment will be one of the future
goals for the group that takes over this project.
22

4.0 ENGINEERING STANDARDS AND CONSTRAINTS
4.0.1. Social
It is our duty to ensure that our internalization assays are reproducible with less
than a 3 fold difference for the drug receptors IC50 and EC50 values. In addition,
our assay has to be robust with time intervals easily adjustable for testing on
other drug compounds. Our project does not have any end users outside of our
testing facilities. We must ensure that others inside of the company can
reproduce our assays and utilize them for drug discovery much after our
departure from the company. Once our assays have been optimized it is
Multispan’s sole responsibility on how these tests are used and to what end
purposes. This area is beyond our scope of research and we have no control on
what our assays will be used once optimized.

4.0.2. Ethical
The ethical ramifications of our project revolves in collaborating with customers
who have had a good track record and paperwork to prove that their drug
compounds required for screening are safe and intended for therapeutic medical
uses. The internalization assays we are attempting to engineer are simply a tool
used for analysis of data to test for the rate of the drug receptor entering into the
cell. As a result, it is both the company and our responsibility to ensure that the
screening of a particular drug target will not lead to unintended consequences
such as the massive manufacturing of deadly toxins. Our obligation as student
researchers is to perfect our assays while most of the ethical decisions lies in the
CEO of Multispan. We have not been required to sign non-disclosure
agreements; theoretically we can legally share our information and data with
anyone we please. Ethically, however, we are required to maintain the integrity of
our research by only sharing information with our advising and funding parties.
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4.0.3. Manufacturability
To ensure integrity our internalization assays must be reproducible with at least 3
individual experiments ran on separate days. In addition, our service has to be
robust with time intervals easily adjustable for testing on new drugs. Multispan’s
proprietary technology and assay procedures build upon data from previous
experiments to confirm the validity of our data. We can also go back to literature
to ensure we meet the theoretical internalization rates and concentrations with
known ligands in order to ensure accuracy. Multispan’s proprietary technology
and assay procedures build upon data from previous experiments to confirm the
validity of our data. We can also go back to literature to ensure we meet the
theoretical internalization rates and concentrations with known ligands in order to
ensure accuracy.

4.0.4 Political
Experiments are all conducted at company headquarters without the risk of
outside intrusion. Results will be shared amongst the two of us through Dropbox
and Google documents as well as with our academic and industry advisors. No
one else should know or have access to our data and research without implicit
consent from Multispan Inc. Errors is to be expected and necessary to report and
for conducting proceeding experiments. Without reporting errors, similar ones
may appear again in the future. All of our data, whether valid or not, should be
shared amongst ourselves and made our advisors aware of its existence. No
data should go without being questioned and analyzed.

4.0.5. Safety
The physical risks of our project are minimal. However, we must focus on
confidentiality. Each specific ligand/ receptor is unknown to us because they
are proprietary compounds from customers of Multispan. They don’t know nor
are they allowed to know. Physical safety is not exactly a factor in this project
but we are dealing with chemicals in a lab setting which may be flammable
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and toxic. Therefore, we must observe good laboratory practice. The
confidentiality of this project revolves among the two of us working on it and the
company itself. It would then be up to the company's dissection who it shares our
findings with.
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6.0. Summary and Conclusion

Initially our project goal was to develop internalization assays for the entire
prostanoid family. Realistically, this was improbable as our team did not have
prior biochemistry background before the project. However, we did not imagine
that it would be such a difficult task to validate three receptors for agonist
response. The difficulty comes in the constraints of the available literature
research on the internalization of prostanoid receptors and which compounds we
have available at Multispan Inc. In addition, time was a significant limiting factor
as we were balancing between classes, projects, job applications, extracurricular
activities, and senior design. We were well aware that the tradeoff of running
Multispan Inc.’s platform would be time consuming but the tradeoff would be
accuracy to the level of individual cells.

In regards to the receptors which did internalize, over 50% internalization was
observed for EP4 and EP1 by being activated by PGE 2 and iloprost respectively.
EP4 internalized over the time intervals of 30 and 60 minutes with an EC 50 value
of 5.2 nM and 5.6 nM respectively. Because both of the EC50 values fall so close
to each other, we cannot dismiss either time points. Most importantly, the EC50
value falls within the range of other assays, the deviation in MFI is extremely low
for each dilution of the drug, and the experiment is performed in triplicates. For
EP1, the receptor internalized after 60 minutes after being activated by iloprost.
The experiment is validated because it falls within range of the values presented
for both IUPHAR and Multispan Inc.’s database for other assays. In addition, the
results were reproducible in 3 experiments. In the third experiment, we observed
over 40% internalization for the TP receptor after 120 minutes. It was extremely
difficult to find literature research on TP internalization and Multispan Inc. did not
have any of the known potent agonists. As a result, we took a bit of a risk and
chose PGD2 with the knowledge of its binding affinity value and chose a starting
concentration accordingly. We were able to successfully replicate the experiment
twice with an extremely small deviation between the MFI for different
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concentrations of the drug compound. More importantly, the EC50 value falls a
little over the converted value listed from IUPHAR for other assays. Because we
were unable to repeat this experiment a third time, we cannot completely state
that the assay is validated but at the same time we cannot completely dismiss
the results.

Besides EP1, EP4 and TP, we also ran EP2 and DP1 assays but we were
unsuccessful in our attempt to internalize the receptors. For the most part in the
beginning of the project, we struggled on technique so our results for EP2 was
not logical at all. The drug we used for EP2 was iloprost because it was actually
the protocol initially developed by Dr. Venkhat. We did not attempt to internalize
the receptor again until the spring quarter. The results showed very little
internalization with iloprost when we ran it again. For DP1, we were initially able
to obtain some promising results with over 30% internalization but the results
were not repeatable the second time. This may be due to many factors such as
unhealthy cells, inconsistent technique, or the drug compound may have been
contaminated.

In the future, we hope that the individuals who continue this project obtain the
IC50 values for EP1 and EP4 receptors. In addition, we would hope that the next
group would repeat our TP assay experiment and finish the validation and move
on to obtaining IC50 values. By obtaining the IC50 value, we will then have the
complete assay for each receptor to test on libraries of compounds.
Up to this point, we have been able to utilize Multispan’s proprietary cell lines to
overexpress a few GPCRs. We have activated EP1, EP4, and TP with iloprost,
PGE2, and PGD2. In turn, we were able to obtain EC50 values and specific time
intervals for receptor internalization. With these assays we are attempting an in
vitro model of an agonist dose response. These assays monitor receptor
activation and internalization. In turn, they become powerful tools for the
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discovery of novel therapeutics to test against libraries and to screen from a few
thousand to millions of compounds.
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7.0 APPENDICES
7.1 Customer Needs Survey

Interviewer: William Truong
Method: E-mail
Dr. Helena Mancebo, CEO Multispan Inc.
1. Who are Multispan’s competitors for the internalization assays?
-No one else is offering internalization assay that we know of.
2. What are Multispan’s prices per internalization assay for companies?
-We can’t really share pricing information. It’s privileged information between Multispan
and its customers

3. Is time a factor that is weighed heavily for the internalization assays?
It’s all driven by biology---i.e. How long it takes for measurable amount of each receptor
to be internalized following receptor activation.

4. During this internship at Multispan, what will be required for Josergio and I?
You will need to perform the following:
1.

Learn and perfect cell culture, FACS, and assay development techniques.

2.

Independently plan and carry out experiments from start to finish.

3.

After each experiment, critically analyze data, troubleshoot and design the follow-

up experiments.
4.

Perform literature search, deepening understanding in receptor protein turnover

and trafficking. Seek advice regularly by asking prepared questions.
6.

Apply rigor and diligence to your work at all levels.
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5. What are the requirements for the results of each internalization assay
(customer’s perspective)?
1. Reproducibility: Each assay need to be shown with less than 3 fold differences
EC50s or IC50s in 3 independent experiments to be considered “validated”.
2. Timeline: Develop validated internalization assays for all targets within each assigned
receptor family by the end of the project.

Interviewer: William Truong
Method: In-Person
Dr. Ricai Han, Senior Scientist Multispan Inc.

1. Is Multispan aware of any specific information regarding the drugs sent by the
companies such as Johnson and Johnson?
Multispan does not know the affinity of the receptor or other specific information about it.
We also don’t know whether compound could affect trigger signal transduction.

2. Without knowing any specifics about the drugs, what does a researcher need
to do in order to perform these internalization assays?
We need to characterize the function and activities of how it would affect surface
expression. In addition, we need to find the internalization factor.

3. What is expected of us after we are able to report an internalization assay for
one GPCR receptor?
After completing this task we may move onto other assays like cAMP, Beta etc.

4. As a scientist, what is your take on weighing in time as an important variable
for these experiments?
It is desired but probably not yet achievable for speeding up the time of internalization
for each receptor. Each internalization time varies based on the receptor type.
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Interviewer: William Truong, Josergio Zaragoza
Method: In-Person
Dr. Radhika Venkhat, R & D Manager, Multispan Inc.

1. Can you share with us your experience with internalizing receptors?
-I have worked with many GPCRs for internalization but for your assigned family, I have
only worked with DP2.

2. What issues did you face during your internalization assays?
The first issue is framing the time point of internalization for an unknown compound with
a receptor. The reason is that there is a rapid recycling time frame for some receptors
and it is essential to grasp this specific time interval in order for us to not miss the point
of internalization.

3. How do you determine the agonists and antagonists that are used for each
assay?
Agonists and antagonists are chosen base on those reported from literature research
and analysis. Some internalization is derived from external factors. Others may require
internalization with other receptors (Ex: some articles have noted that EP2 internalizes
with EP4.

4. What signaling pathways did you utilize during your internalization assays?
I only checked on surface independent pathway not overexpressing receptors. I did not
check the dependent downstream signaling pathway.

5. What is your advice in your approach towards coming up with an
internalization assay for our families of receptors?
Keep practicing on the technique and running the assays. Once you master the
technique and read more on the literature you would then learn whether there’s a need
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to increase or decrease drug concentration and whether the time intervals need to be
shorter or longer.
7.1.1 Detailed Product Design Specification
Table A-1. Detailed product design specification breaking down three main categories:
assay, confidentiality and deliverables.
Category

Assay

Confidentiality

Requirement

Importance

EC50,IC50 must be found
to be accurate within a
threefold difference

High- The minimum threshold of
internalization of the receptor
with any given agonist must be
accurately determined for the
assay to be valid.

Validated internalization
assay for all targets in
prostanoid Family

Med-Low- Some receptors in
our family may require external
factors or co-internalization with
another receptor in order to
internalize which is out of our
abilities. Not all receptors in all
families have been identified,
studied, or found.

Assay must be
reproducible in 3 individual
runs

High- In order to cut down on
time, costs, and to have
complete validation this must be
true

Proprietary procedures,
materials and information
must remain within
Multispan Inc.

High- All recombinant cells and
reagents must remain inside the
company. Procedures should not
be shared with individuals
outside of advisors.

Ligand affinity and
properties provided by
other companies will not
be known and should not
be investigated for

Low- It is not very likely that we
will be working with outside
ligands. The properties of these
ligands will not be provided.
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purposes outside assays.

Deliverables

Data must be complete and High- Any discrepancies between the
under final conditions for two data will cause doubt in the user and
receptor families
there needs to be controlled and
monitored conditions

7.1.2. Detailed Budget Breakdown
Table A-2. Detailed budget breakdown and costs of the materials, including the vendor,
quantity, unit, and description of the item used for research.
Vendor
VWR
VWR

BD
Bioscience
s
VWR
VWR
VWR
VWR
VWR
Invitrogen

Description
15 mL conical tubes
96-Well Plates,
Polypropylene, VBottom
Calibrite 3 color beads

Nonsterile reservoirs
Hyclone FBS
2 mL pipets
10 mL pipets
Trypsin

VWR
VWR

Gibco DMEM w/
GlutaMAX
10 mL pipets
Dialyzed FBS (hyclone)

VWR

Cryovials

VWR

VWR

Eppendorf* Safe-Lock
Polypropylene, 0.5 mL
P1000 tips, with filter,
sterile
T-25 flasks

VWR

25 mL pipets

VWR

Price
68.00
106.6
4

Unit
500/case
100/case

257.5
0

1 box

46.64
169.8
4
50.38
27.85
33.00

100/case
1 bottle

1
3

$78.90
$541.78

500/case
200/case
6x100mL/pac
k
1 case
(10x500mL)
200/case
500 mL

1
1
1

$59.99
$37.46
$52.59

500/case

1

500/case

1

196.7
8
27.85
385.3
9
100.3
5
40.80

Quantity
1
1

Cost
$79.75
$144.51

1
$318.09

1
1
3

$230.87
$41.93
$1,234.9
3
$179.11

$47.31
44.00

768/pack

1

67.85

100/case

1

68.00

200/case

1

$66.25
$90.10
$90.25

VWR

6-well plates

57.50

50/case

1
$79.75
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VWR

96-well plates

67.00

50/case

1
$89.25

VWR
Office
Depot
VWR
VWR
VWR

15 mL conical tubes
Bleach

2.96

DMEM
PBS 1X W/O CA+MG
6X500ML
5 mL pipets

35.94
35.94

VWR
VWR
VWR

Sterile reservoirs
T-75 flasks
medium Nitrile gloves

VWR

Universal Fit Tips, Low
Retention (p20)
96-Well, U-Bottom
Assay Plate
DME/F12 media
Aspirating pipets
P20, P200 refills
P1000 tips, no filter,
non-sterile
Conical-Bottom
Centrifuge Tube with
Flat Cap, 50 mL
anti-FLAG-RPE
Conjugate (FACS Ab)

VWR
VWR
VWR
VWR
VWR
VWR

ProZyme

BD

68.00

BD FACSFlow Sheath
Fluid
Total Expenses

500/case

1
1

6/pack
6x500 mL

6
1

$90.25
$3.48
$223.09
$43.39

26.60
95.39
63.20
132.7
9
104.0
0
125.4
7
8.2
30.20
18.60
10.00

200/case

1

100/case
60/case
1000/case

1
1
1

4800/case

1

$44.48
$106.74
$77.70
$144.14

$117.53
50/case
500 mL/each
200/case
960/pack
576 tips/pack

1
6
1
1
1

$139.30
$59.38
$40.38
$28.78
$20.18

80.34

500/case

1
$88.37

650.0
0

1 mg/vial

31.00

20 L/each

2
$1,403.0
0
3
$93.00
$6,185.9
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7.2 Glossary of Terms
Ligand: substance that binds to a chemical entity to form a larger complex
Agonist: chemical that binds to a receptor and triggers a response
Antagonist: ligand that blocks or dampens agonist-mediated responses
EC50: dosage (concentration) which produces 50% of a maximum given effect
IC50: half maximal inhibitory concentration of a compound to inhibit a biological or
biochemical effect
Internalization: endocytosis (when cell engulfs molecule or receptor) of GPCR
Clathrin: protein that plays a major role in the formation of vesicles
Arrestin: small family of proteins important for regulating signal transduction
Flow Cytometry: technique for counting and examining microscopic particles by
suspending them in a stream of fluid and passing them through an electronic detection
zone
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7.3. Project Management Timeline
Fall Quarter
Week 5:


Continue training on cell culturing and shadow Dr. Venkat on cell assay
techniques



Write up budget proposal to submit to both senior design and engineering
department for grant



Continue looking up literature research for prostanoid receptors



Learn how to use the live cell flow cytometer



Run first GPCR internalization assay Friday one of our receptors of interest



Send e-mails or meet up with Researchers for customer needs report

Week 6:


Review Internalization Assay procedure and notes



Continue Literature research on the internalization procedures done on two
interested families of receptors (EP1 and EP2)



Work on Customer needs report to submit Friday



Practice using FACS machine



Learn how to use FACS software

Week 7:


Meet up with Dr. Mancebo and Dr. Zhang to talk about our progress and clear up
direction for project



Gather literature research and come up with protocol for internalization assay



Go over internalization protocol with Dr. Venkat and work on skills required for
assay



Start working on CDR draft

Week 8:


Continue literature research on EP1 and EP2 and decide whether these two
receptors are viable starting point.



Continue practice with FACS machine, internalization assays and begin looking
into protocols for cAMP assays if needed
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Finish CDR draft and turn in Friday

Week 9:


At this point we should be really familiar with cell culture , passaging of the cells,
and become more comfortable with working on internalization assays



Come up with an alternative method such as modifying agonist or antagonist
receptors if internalization assay was not successful for the two target GPCRs up
to this point.



Decide whether or not to move on to another receptor family and receive
feedback from our two advisors



Start practicing for presentation

Week 10:


Trouble shooting/catch up week



Continue literature research and move on to another prostanoid receptor to
prepare for next quarter



Presentation slide package due



Wrap up experiment and submit results and work throughout quarter to adviser to
see what direction we need to head to next quarter



Work on CDR draft to submit

Week 11: (Finals Week)


Follow up on any work that needs to be completed



Begin scheduling for working times for next quarter



Review over data to see if there is a need to rerun any experiment



Perform research on prostanoid receptor pathway of choice and start on a
protocol for Andy and Dr. Mancebo to review before heading off to break

Winter Quarter:
-Start on internalization assays on different receptor of interest
-Work on detailed drawings due near middle of quarter
-Work on assembly drawings and initial hardware due end of quarter
-Work on presentations for senior design
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-Work on Poster for engineering events if we are funded by engineering
-Start developing internalization assays on different receptors of interest
-Work on and finish end of quarter report
-Plan schedule for spring quarter and set up new meeting times for working at
Multispan and meetings with advisor

Spring Quarter:
-Work on the finalization stages of our assay development
-Continue practicing on public speaking skills for presentation
-Finalize data and results and work on additional receptors if ample time is left
and enough literature research is obtained to support assay analysis
-Prepare for senior design conference
-Start early on putting together senior design thesis
-Prepare poster board for open house
-Finalize slides for senior design presentation
-Reserve the last day before the presentation to relax and be ready for the
presentation
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7.4. Extra Experiments
7.4.1. EP1

Figure A. Preliminary EC50 plot for EP1 which includes 30, 60, and 90 minutes.

7.4.2. EP4

Figure B. Preliminary EC50 plot for EP4 which includes 30, 60, 90, and 120 minutes.
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7.4.3. DP1

Figure C. DP1 EC50 plot which shows only 90 min and 120 minute. Dose response
curve cannot be fitted for 30 and 60 minutes.
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